{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:40:19Z","timestamp":1773027619138,"version":"3.50.1"},"reference-count":18,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>This research report assessed the differences in resistance rates and antimicrobial usage-versus-susceptibility relationships of Pseudomonas aeruginosa found in various hospital patient care areas. A simplified case control study was also performed to identify patient-specific risk factors associated with cefepime-resistant P. aeruginosa isolates. Last, we determined the consequence of combining mucoid and non-mucoid derived antimicrobial susceptibilities of P. aeruginosa into hospital antibiograms. Overall, susceptibility rates remained lower in the intensive care units (ICUs) compared to the non-ICU patient care areas, except for cefepime over the last time period. Cefepime utilization and antimicrobial-resistance rates among P. aeruginosa isolates had a significant relationship. Decreased meropenem exposure was associated with lower resistance rates relative to cefepime. Risk factors independently associated with cefepime-resistant P. aeruginosa were structural lung disease, ICU admission, recent third generation cephalosporin use, frequent hospital admission and non-urine isolates. Large and statistically significant differences were observed between non-mucoid and combined percent susceptibility data for aminoglycosides. To control antimicrobial resistance and optimize initial empiric antimicrobial therapy, antimicrobial susceptibility and utilization patterns in specific patient care areas should be monitored and risk factors for antimicrobial resistance should be assessed. Mucoid strains of P. aeruginosa should not be included into antimicrobial susceptibility data as this may underestimate activity of most antipseudomonal agents.<\/jats:p>","DOI":"10.3390\/ph3041070","type":"journal-article","created":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T11:14:36Z","timestamp":1270120476000},"page":"1070-1083","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lessons Learned from Surveillance of Antimicrobial Susceptibilities of Pseudomonas aeruginosa at a Large Academic Medical Center"],"prefix":"10.3390","volume":"3","author":[{"given":"Brett H.","family":"Heintz","sequence":"first","affiliation":[{"name":"Clinical Pharmacy, San Francisco School of Pharmacy, University of California, 521 Parnassus Avenue UCSF Box 0622, Room C-152 San Francisco, CA 94143, USA"},{"name":"Department of Pharmaceutical Services, University of California Davis Health System, Sacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenana","family":"Halilovic","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, University of California Davis Health System, Sacramento, CA 95817, USA"},{"name":"Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, 3601 Pacific Avenue, Stockton, CA 95211, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2010,4,1]]},"reference":[{"key":"ref_1","first-page":"2835","article-title":"Pseudomonas aeruginosa","volume":"2","author":"Mandell","year":"2010","journal-title":"Principles and Practice of Infectious Diseases"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jac\/dkg102","article-title":"Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections","volume":"51","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/313916","article-title":"Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas","volume":"31","author":"White","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1086\/511640","article-title":"Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy","volume":"44","author":"Polk","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","unstructured":"(2008). ATC\/DDD Index, WHO Collaborating Centre for Drug Statistics Methodology."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/511864","article-title":"Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute","volume":"44","author":"Hindler","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1086\/503342","article-title":"Analysis and presentation of cumulative antimicrobial susceptibility data (antibiograms): substantial variability across medical centers in the United States","volume":"27","author":"Lautenbach","year":"2006","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1086\/505921","article-title":"Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy","volume":"27","author":"Binkley","year":"2006","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lalani, T., Varkey, J.B., Drew, R., Harrell, L., McGarry, S., Engemann, J.G., Johnson, M.D., and Kaye, K.S. (2008). Analysis of two- and three-year trends in antimicrobial resistance in intensive care units using unit-specific antibiograms. Scand. J. Infect. Dis., 1\u20133.","DOI":"10.1080\/00365540801971403"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1086\/322677","article-title":"Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli","volume":"33","author":"Harbarth","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2146\/ajhp070435","article-title":"Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance","volume":"65","author":"Paladino","year":"2008","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1345\/aph.1H377","article-title":"Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms","volume":"40","author":"Bosso","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","article-title":"Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy","volume":"35","author":"Barcenilla","year":"2007","journal-title":"Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(04)01108-9","article-title":"Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis","volume":"4","author":"Safdar","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Paul, M., Silbiger, I., Grozinsky, S., Soares-Weiser, K., and Leibovici, L. (2006). Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev., CD003344.","DOI":"10.1002\/14651858.CD003344.pub2"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/JCM.01716-06","article-title":"Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2)","volume":"45","author":"Juretschko","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"ref_18","unstructured":"Noskin, G. (2006). Contemporary Diagnosis and Management of Antimicrobial-Resistant Bacteria, Handbooks in Healthcare Co.. [1st ed.]."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/4\/1070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:02:01Z","timestamp":1760220121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/4\/1070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,4]]}},"alternative-id":["ph3041070"],"URL":"https:\/\/doi.org\/10.3390\/ph3041070","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,1]]}}}